Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …

Background Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in
HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover …

We aimed to probe the functions and possible mechanisms of empagliflozin in doxorubicin
(Dox)-caused cardiotoxicity. First, a cardiotoxicity rat model was built by continuously …

Doxorubicin (Dox) exhibits a high efficacy in the treatment of numerous types of cancer.
However, the beneficial cytotoxic effects of Dox are often accompanied by an increase in the …

Objectives Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been confirmed to
reduce the rate of rehospitalization for heart failure and cardiovascular death in diabetic …

Cardiovascular complications contribute to the major mortality and morbidity in type 2
diabetes. Diabetic cardiomyopathy (DCM) is increasingly recognized as an important cause …

Trastuzumab (TZM) is commonly used for target therapy in breast cancer patients with high
HER2 although the cardiotoxicity restricts its clinical usage. DNA damage and ferroptosis …

Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the
main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 …

Hyperglycemia associated with inflammation and oxidative stress is a major cause of
vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a …